PT1436321E - Sintese de analogos de ciclosporina - Google Patents

Sintese de analogos de ciclosporina

Info

Publication number: PT1436321E
Authority: PT; Portugal
Prior art keywords: isomers; cyclosporine; isa; derivatives; mixtures
Prior art date: 2001-10-19

Application number

PT02767027T

Other languages

English (en)

Inventor

Selvaraj Naicker

Randall W Yatscoff

Robert T Foster

Abel Mark

Jayaraman Seetharaman

Mair Hans-Jurgen

Adam Jean-Michel

Lohri Bruno

Original Assignee

Isotechnika Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-19

Filing date

2002-10-17

Publication date

2006-10-31

2002-10-17 Application filed by Isotechnika Inc filed Critical Isotechnika Inc

2006-10-31 Publication of PT1436321E publication Critical patent/PT1436321E/pt

Links

PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical class CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 title abstract 5
230000015572 biosynthetic process Effects 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
239000000203 mixture Substances 0.000 abstract 5
108010036941 Cyclosporins Proteins 0.000 abstract 2
229930182912 cyclosporin Natural products 0.000 abstract 2
230000037361 pathway Effects 0.000 abstract 2
230000000707 stereoselective effect Effects 0.000 abstract 2
230000001988 toxicity Effects 0.000 abstract 2
231100000419 toxicity Toxicity 0.000 abstract 2
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 abstract 1
229930105110 Cyclosporin A Natural products 0.000 abstract 1
108010036949 Cyclosporine Proteins 0.000 abstract 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract 1
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 abstract 1
238000007239 Wittig reaction Methods 0.000 abstract 1
229910052796 boron Inorganic materials 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
229910052744 lithium Inorganic materials 0.000 abstract 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
125000002524 organometallic group Chemical group 0.000 abstract 1
229910052710 silicon Inorganic materials 0.000 abstract 1
239000010703 silicon Substances 0.000 abstract 1
229910052719 titanium Inorganic materials 0.000 abstract 1
239000010936 titanium Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Nanotechnology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Rheumatology (AREA)
Neurology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Dispersion Chemistry (AREA)
Biotechnology (AREA)
Crystallography & Structural Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Virology (AREA)
Obesity (AREA)

PT02767027T 2001-10-19 2002-10-17 Sintese de analogos de ciclosporina PT1436321E (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US34620101P	2001-10-19	2001-10-19
US37059602P	2002-04-05	2002-04-05

Publications (1)

Publication Number	Publication Date
PT1436321E true PT1436321E (pt)	2006-10-31

Family

ID=26994746

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT06013976T PT1714977E (pt)	2001-10-19	2002-10-17	Síntese de análogos de ciclosporina
PT02767027T PT1436321E (pt)	2001-10-19	2002-10-17	Sintese de analogos de ciclosporina

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT06013976T PT1714977E (pt)	2001-10-19	2002-10-17	Síntese de análogos de ciclosporina

Country Status (27)

Country	Link
US (13)	US6998385B2 (pt)
EP (2)	EP1436321B9 (pt)
JP (3)	JP4261355B2 (pt)
KR (2)	KR101006206B1 (pt)
CN (1)	CN100334106C (pt)
AT (2)	ATE332917T1 (pt)
AU (2)	AU2002331509B2 (pt)
BR (1)	BRPI0213658A8 (pt)
CA (1)	CA2461740C (pt)
CO (1)	CO5580836A2 (pt)
CY (1)	CY1105111T1 (pt)
DE (2)	DE60231570D1 (pt)
DK (2)	DK1436321T3 (pt)
ES (2)	ES2266564T3 (pt)
HR (2)	HRP20040355B1 (pt)
IL (3)	IL160763A0 (pt)
MA (1)	MA27293A1 (pt)
MX (1)	MXPA04003625A (pt)
NO (1)	NO332459B1 (pt)
NZ (1)	NZ531944A (pt)
PL (2)	PL210841B1 (pt)
PT (2)	PT1714977E (pt)
RU (1)	RU2321593C9 (pt)
SI (1)	SI1436321T1 (pt)
TN (1)	TNSN04068A1 (pt)
WO (1)	WO2003033526A2 (pt)
ZA (1)	ZA200402269B (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
ATE332917T1 (de) *	2001-10-19	2006-08-15	Isotechnika Inc	Synthese von cyclosporin-analogen
CA2727642C (en) *	2001-10-19	2014-02-04	Isotechnika Inc.	Synthesis of cyclosporin analogs
WO2004082629A2 (en) *	2003-03-17	2004-09-30	Albany Molecular Research, Inc.	Novel cyclosporins
TW200505946A (en) *	2003-04-08	2005-02-16	Hoffmann La Roche	Process for preparation of cyclosporin a analog
US20040266669A1 (en) *	2003-06-20	2004-12-30	Wu Frank X. H.	Cyclosporin derivatives for the treatment of immune disorders
US7799756B2 (en)	2004-07-29	2010-09-21	Albany Molecular Research, Inc.	Processes for stereoselective synthesis of trans ISATX247
JP2008514702A (ja)	2004-09-29	2008-05-08	エーエムアールテクノロジーインコーポレイテッド	新規シクロスポリン類似体およびそれらの薬学的使用
US7378391B2 (en) *	2004-09-29	2008-05-27	Amr Technology, Inc.	Cyclosporin alkyne analogues and their pharmaceutical uses
US7361636B2 (en) *	2004-10-06	2008-04-22	Amr Technology, Inc.	Cyclosporin alkynes and their utility as pharmaceutical agents
EP1828229A4 (en) *	2004-12-17	2010-06-30	Isotechnika Inc	METABOLITES OF CYCLOSPORINANALOGA
US20080234213A1 (en) *	2005-09-02	2008-09-25	Matthias Wabl	Oncogenic regulatory RNAs for diagnostics and therapeutics
US7459280B2 (en) *	2006-02-27	2008-12-02	Picobella, Llc	Methods for diagnosing and treating kidney cancer
US7696166B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) *	2006-03-28	2010-04-13	Albany Molecular Research, Inc.	Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20070232532A1 (en) *	2006-03-28	2007-10-04	Amr Technology, Inc.	Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US20080267977A1 (en) *	2007-04-26	2008-10-30	Friedrich-Alexander University Of Erlangen-Nuremberg	Combined immunological agent and sensitizing agent for the treatment of cancer
ES2667945T3 (es)	2007-10-08	2018-05-16	Aurinia Pharmaceuticals Inc.	Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
EP2151450A1 (de) *	2008-07-29	2010-02-10	Sandoz AG	Verfahren zur Aufarbeitung von mikrobiologisch hergestellten zyklischen Oligopeptiden
CN102164948A (zh) *	2008-07-30	2011-08-24	伊索技术制药公司	非免疫抑制的环孢菌素类似分子
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
AU2010208071C1 (en)	2009-01-30	2013-06-20	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues for preventing or treating hepatitis C infection
US8481483B2 (en)	2009-02-19	2013-07-09	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
MX338355B (es) *	2009-06-09	2016-04-13	Aurinia Pharmaceuticals Inc	Sistemas de suministro de farmaco topico para uso oftalmico.
US8367053B2 (en)	2009-07-09	2013-02-05	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
US8349312B2 (en)	2009-07-09	2013-01-08	Enanta Pharmaceuticals, Inc.	Proline substituted cyclosporin analogues
US8685917B2 (en)	2009-07-09	2014-04-01	Enanta Pharmaceuticals, Inc.	Cyclosporin analogues
GB0912584D0 (en) *	2009-07-20	2009-08-26	Ucl Business Plc	Cyclosporin conjugates
US8623814B2 (en)	2010-02-23	2014-01-07	Enanta Pharmaceuticals, Inc.	Antiviral agents
KR102011339B1 (ko) *	2010-12-15	2019-08-16	콘트라빌 파마슈티컬스, 인코퍼레이티드	아미노산 1 및 3에서 변형된 사이클로스포린 유사체 분자
US20140050728A1 (en) *	2011-01-28	2014-02-20	Board Of Regents Of The University Of Nebraska	Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
US10429712B2 (en)	2012-04-20	2019-10-01	View, Inc.	Angled bus bar
WO2012145426A1 (en)	2011-04-18	2012-10-26	The Trustees Of Columbia University In The City Of New York	Methods to treat cancer using cyclosporine and cyclosporine derivatives
MX373641B (es)	2011-04-29	2020-05-04	Selecta Biosciences Inc	Nanoportadores sintéticos tolerogénicos para la terapia contra alergias.
AR090964A1 (es) *	2012-05-09	2014-12-17	Novartis Ag	Proceso para la elaboracion de undecapeptidos ciclicos
CA2874548A1 (en)	2012-06-01	2013-12-05	Allergan, Inc.	Cyclosporin a analogs
EP2705856A1 (en)	2012-09-07	2014-03-12	Deutsches Zentrum für Neurodegenerative Erkrankungen e.V.	Compounds for the treatment of neurodegenerative disorders
WO2014085623A1 (en)	2012-11-28	2014-06-05	Enanta Pharmaceuticals, Inc.	Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
CA2908645A1 (en)	2013-04-01	2014-10-09	Allergan, Inc.	Microsphere drug delivery system for sustained intraocular release
CN105283175A (zh)	2013-05-03	2016-01-27	西莱克塔生物科技公司	用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
CN105324708B (zh)	2013-06-18	2020-02-14	唯景公司	非矩形形状上的电致变色设备
SG11201601274QA (en)	2013-08-26	2016-03-30	Enanta Pharm Inc	Cyclosporin analogues for preventing or treating hepatitis c
KR20170045344A (ko)	2014-09-07	2017-04-26	셀렉타 바이오사이언시즈, 인크.	항-바이러스 전달 벡터 면역 반응을 약화시키기 위한 방법 및 조성물
WO2016073480A1 (en)	2014-11-03	2016-05-12	Enanta Pharmaceuticals, Inc.	Novel cyclosporin analogues for preventing or treating hepatitis c infection
HK1246276A1 (zh) *	2014-12-17	2018-09-07	Verrica Pharmaceuticals, Inc.	斑蝥素和生物活性斑蝥素衍生物的商业上可行的合成
WO2016112321A1 (en)	2015-01-08	2016-07-14	Allergan, Inc.	Cyclosporin derivatives wherein the mebmt sidechain has been cyclized
CN106554392B (zh) *	2016-11-21	2019-10-25	石家庄中天生物技术有限责任公司	一种高纯度环孢菌素衍生物stg-175的制备方法
JP7523909B2 (ja)	2017-03-11	2024-07-29	セレクタバイオサイエンシーズインコーポレーテッド	抗炎症剤および免疫抑制剤を含む合成ナノキャリアによる組み合わせ処置に関連する方法および組成物
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
US10286036B2 (en)	2017-05-12	2019-05-14	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
US11147790B2 (en)	2017-06-06	2021-10-19	Verrica Pharmaceuticals Inc.	Treatment of cutaneous disorders
JP7497980B2 (ja)	2017-06-15	2024-06-11	ヴェリカファーマシューティカルズインコーポレーテッド	体表面の障害の処置のためのデバイスおよび方法
USD900312S1 (en)	2017-06-15	2020-10-27	Verrica Pharmaceuticals, Inc.	Applicator
CA3078325A1 (en)	2017-10-04	2019-04-11	Verrica Pharmaceuticals Inc.	Synthesis of cantharidin
US11584779B2 (en)	2018-10-19	2023-02-21	Teva Pharmaceuticals International Gmbh	Solid state forms of voclosporin
CA3181952A1 (en)	2020-05-07	2021-11-11	Aurinia Pharmaceuticals Inc.	Methods of treating or preventing coronavirus infection
EP4201952A1 (en)	2021-12-21	2023-06-28	Curia Spain, S.A.U.	Process for the controlled synthesis of voclosporin
WO2025119925A1 (en)	2023-12-05	2025-06-12	Medichem, S.A.	Process for preparing voclosporin

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US525590A (en) *		1894-09-04		canda
CH614931A5 (pt)	1975-11-04	1979-12-28	Sandoz Ag
US4210581A (en)	1975-11-04	1980-07-01	Sandoz Ltd.	Organic compounds
US4117118A (en)	1976-04-09	1978-09-26	Sandoz Ltd.	Organic compounds
DK25877A (da)	1977-01-21	1978-08-15	Nordisk Insulinlab	Fremgangsmaade til udvinding af renset albumin fra blodplasma
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4160452A (en)	1977-04-07	1979-07-10	Alza Corporation	Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
CH628022A5 (en)	1977-05-10	1982-02-15	Sandoz Ag	Process for the preparation of an antibiotic derivative
DE2819094A1 (de)	1977-05-10	1978-11-23	Sandoz Ag	Cyclosporin-derivate, ihre verwendung und herstellung
CH630061A5 (en)	1977-05-10	1982-05-28	Sandoz Ag	Process for the preparation of an antibiotic derivative
CH630062A5 (en)	1977-05-23	1982-05-28	Sandoz Ag	Process for the preparation of an antibiotic derivative
SE448386B (sv)	1978-10-18	1987-02-16	Sandoz Ag	Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en)	1979-03-12	1980-05-06	Merck & Co., Inc.	Antibiotic A43F
EP0098456B1 (en)	1980-02-14	1989-05-24	Sandoz Ag	Peptides comprising a (1s,2r,3r)- or (1r,2s,3s)-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptane or -hept-5-ene residue useful in the total synthesis of cyclosporins, and processes for their production
US4396542A (en)	1980-02-14	1983-08-02	Sandoz Ltd.	Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
FR2487198A1 (fr)	1980-07-28	1982-01-29	Berri Balzac Sa	Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4304641A (en)	1980-11-24	1981-12-08	International Business Machines Corporation	Rotary electroplating cell with controlled current distribution
DE3260468D1 (en)	1981-01-09	1984-09-06	Sandoz Ag	Novel cyclosporins
CH667274A5 (de)	1984-03-23	1988-09-30	Sandoz Ag	Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NZ212051A (en)	1984-05-18	1988-10-28	Univ Australian	Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5639724A (en)	1984-07-24	1997-06-17	Sandoz Ltd.	Cyclosporin galenic forms
GB8422253D0 (en)	1984-09-04	1984-10-10	Sandoz Ltd	Organic compounds
US5169773A (en)	1984-10-04	1992-12-08	Sandoz Ltd.	Monoclonal antibodies to cyclosporins
DE3587342T2 (de)	1984-10-04	1993-12-02	Sandoz Ag	Cyclosporine.
EP0194972B1 (en)	1985-03-11	1992-07-29	Sandoz Ag	Novel cyclosporins
US5047512A (en)	1985-05-03	1991-09-10	Handschumacher Robert E	Immobilized cyclophilin and methods of using such
DE3531597A1 (de)	1985-09-04	1987-03-05	Bioferon Biochem Substanz	Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4765980A (en)	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
CH670644A5 (pt) *	1986-12-18	1989-06-30	Lonza Ag
US4764503A (en)	1986-11-19	1988-08-16	Sandoz Ltd.	Novel cyclosporins
US4963683A (en)	1986-12-18	1990-10-16	Sri International	Process for preparing polyoxa tetracyclic compounds
HU205861B (en)	1986-12-19	1992-07-28	Sandoz Ag	Process for producing hydrosole of pharmaceutically effective material
US5084441A (en)	1987-03-04	1992-01-28	Shaw Jack M	Acetylated low density lipoproteins: a delivery system to phagocytic cells for stimulating immunologic response and host resistance
US5427960A (en)	1987-03-27	1995-06-27	Abbott Laboratories	Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
EP0283801A3 (en)	1987-03-27	1990-05-30	Abbott Laboratories	Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US5239057A (en) *	1987-03-27	1993-08-24	Abbott Laboratories	Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
US4885276A (en)	1987-06-03	1989-12-05	Merck & Co., Inc.	Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en)	1987-06-03	1989-01-17	Merck & Co., Inc.	New cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja)	1987-06-04	1997-01-29	三共株式会社	シクロスポリン製剤
EP0296122B1 (en)	1987-06-17	1993-09-29	Sandoz Ag	Cyclosporins and their use as pharmaceuticals
EP0296123B1 (en)	1987-06-19	1994-08-31	Sandoz Ag	Cyclic peptolides
GB2206119B (en)	1987-06-22	1990-10-31	Merck & Co Inc	A new cyclosporin derivative with modified "8-amino acid"
EP0373260B1 (en)	1987-06-22	1994-03-09	Merck & Co. Inc.	Cyclosporin derivatives with modified "8-amino acid"
GB8717299D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Peptides
GB8717300D0 (en)	1987-07-22	1987-08-26	Nat Res Dev	Cyclosporins
GB2207678A (en)	1987-08-03	1989-02-08	Merck & Co Inc	Novel immunosuppressive fluorinated cyclosporin analogs
US5227467A (en)	1987-08-03	1993-07-13	Merck & Co., Inc.	Immunosuppressive fluorinated cyclosporin analogs
US4963362A (en)	1987-08-07	1990-10-16	Regents Of The University Of Minnesota	Freeze-dried liposome mixture containing cyclosporin
US4839342A (en)	1987-09-03	1989-06-13	University Of Georgia Research Foundation, Inc.	Method of increasing tear production by topical administration of cyclosporin
EP0391909B1 (en)	1987-09-03	1994-08-17	The University Of Georgia Research Foundation, Inc.	Ocular cyclosporin composition
US5089390A (en)	1987-09-04	1992-02-18	Syntex (U.S.A.) Inc.	2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4866036A (en)	1987-10-05	1989-09-12	Merck & Co., Inc.	Dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose compositions and methods of use in aids-immunocompromised human hosts
US4868157A (en)	1987-10-05	1989-09-19	Merck & Co., Inc.	Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4868155A (en)	1987-10-05	1989-09-19	Merck & Co., Inc.	Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US5236899A (en)	1987-11-16	1993-08-17	Merck & Co., Inc.	6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US4914188A (en)	1987-11-16	1990-04-03	Merck & Co., Inc.	Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
GB8729153D0 (en)	1987-12-14	1988-01-27	Efamol Ltd	Fatty acid compositions
US5693760A (en)	1988-04-14	1997-12-02	Incyte Pharmaceuticals, Inc.	Method of causing selective immunosuppression using HL-60 related lectins
KR0144358B1 (ko)	1988-04-21	1998-07-15	피. 라이달 크리스텐슨	비타민 d 동족체
JPH0774799B2 (ja)	1988-04-28	1995-08-09	積水化学工業株式会社	血中成分の測定法
EP0430968B1 (en)	1988-05-02	1996-11-20	PHANOS TECHNOLOGIES, Inc.	Compounds, compositions and method for binding bio-affecting substances to surface membranes of bio-particles
US5013719A (en)	1988-05-13	1991-05-07	Merrell Dow Pharmaceuticals Inc.	Method of effecting immunosuppression
DE3927804A1 (de)	1988-08-24	1990-03-01	Boehringer Ingelheim Kg	Verwendung von paf-antagonisten zur behandlung von autoimmunerkrankungen
WO1990002727A1 (fr)	1988-09-14	1990-03-22	Yoshitomi Pharmaceutical Industries, Ltd.	Immunodepresseur
KR0148748B1 (ko)	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
US5342625A (en)	1988-09-16	1994-08-30	Sandoz Ltd.	Pharmaceutical compositions comprising cyclosporins
JPH02124100A (ja)	1988-11-02	1990-05-11	Tonen Corp	プロリルイソメラーゼの使用方法
US5632991A (en)	1988-11-14	1997-05-27	Brigham & Women's Hospital	Antibodies specific for E-selectin and the uses thereof
AU630901B2 (en)	1988-12-02	1992-11-12	Children's Research Institute	Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
US5698448A (en)	1988-12-02	1997-12-16	Soldin; Steven J.	Immunosuppressive drug binding proteins and use
JPH04502328A (ja)	1988-12-05	1992-04-23	ザ・トラステイーズ・オブ・コロンビア・ユニヴアーシテイ・イン・ザ・シテイ・オブ・ニユー・ヨーク	シクロスポリンａの新規誘導体、それに対する抗体及びその使用
EP0372541A1 (en)	1988-12-09	1990-06-13	G.D. Searle & Co.	Method for imparting immunosuppression
US5100889A (en)	1989-04-03	1992-03-31	E. R. Squibb & Sons, Inc.	7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5153327A (en)	1988-12-23	1992-10-06	E. R. Squibb & Sons, Inc.	7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
GB2227244A (en)	1989-01-19	1990-07-25	Merck & Co Inc	Immunosuppressive fluorinated cyclosporin analogs
US4996193A (en)	1989-03-03	1991-02-26	The Regents Of The University Of California	Combined topical and systemic method of administration of cyclosporine
US5540931A (en)	1989-03-03	1996-07-30	Charles W. Hewitt	Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5401731A (en)	1989-06-29	1995-03-28	Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab)	Vitamin D analogues
US5068247A (en)	1989-07-07	1991-11-26	Yoshitomi Pharmaceutical Industries, Ltd.	2-aminopentanoic acid compounds and their use as immunosuppressants
GB8915770D0 (en)	1989-07-10	1989-08-31	Leo Pharm Prod Ltd	Chemical compounds
US5665543A (en)	1989-07-18	1997-09-09	Oncogene Science, Inc.	Method of discovering chemicals capable of functioning as gene expression modulators
US5284826A (en)	1989-07-24	1994-02-08	Sandoz Ltd.	0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
GB8916901D0 (en)	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US5356633A (en)	1989-10-20	1994-10-18	Liposome Technology, Inc.	Method of treatment of inflamed tissues
CS277471B6 (cs)	1989-11-16	1993-03-17	Alexandr Rndr Csc Jegorov	Deriváty cyklosporinu A
CS277472B6 (cs)	1989-11-16	1993-03-17	Alexandr Rndr Csc Jegorov	Způsob výroby derivátů cyklosporinu A
US5514788A (en)	1993-05-17	1996-05-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5591623A (en)	1990-08-14	1997-01-07	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of cell adhesion
US5129884A (en) *	1990-01-16	1992-07-14	Dysarz Edward D	Trap in barrel one handed retracted intervenous catheter device
US5270419A (en)	1990-01-19	1993-12-14	Nova Pharmaceutical Corporation	Polyanhydrides of oligomerized unsaturated aliphatic acids
US5171812A (en)	1990-01-19	1992-12-15	Nova Pharmaceutical Corporation	Polyanhydrides of oligomerized unsaturated aliphatic acids
US5214130A (en)	1990-02-27	1993-05-25	Merck & Co., Inc.	Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5122511A (en)	1990-02-27	1992-06-16	Merck & Co., Inc.	Immunosuppressive cyclosporin analogs with modified amino acids at position-8
DE4013910A1 (de)	1990-04-26	1991-10-31	Schering Ag	Kombinationspraeparat zur immunsuppressiven therapie
US5385915A (en)	1990-05-16	1995-01-31	The Rockefeller University	Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9017890D0 (en)	1990-08-15	1990-09-26	Leo Pharm Prod Ltd	Chemical compounds i
ES2084069T3 (es)	1990-08-15	1996-05-01	Abbott Lab	Reactivos de inmunoensayo y metodo para la determinacion de ciclosporina.
EP0547140A4 (en)	1990-09-06	1993-10-13	The Australian National University	Immunosuppressant composition
ES2095926T5 (es)	1990-11-02	2001-02-16	Novartis Ag	Cyclosporins.
ATE142344T1 (de)	1990-11-20	1996-09-15	Behringwerke Ag	Immunotest für cyclosporin
ATE127528T1 (de)	1991-04-06	1995-09-15	Dresden Arzneimittel	Verfahren zur fermentativen herstellung und isolierung von cyclosporin a sowie neue cyclosporin- bildende stämme.
ZA923641B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
GB9113872D0 (en)	1991-06-27	1991-08-14	Sandoz Ag	Improvements in or relating to organic compounds
US5578444A (en)	1991-06-27	1996-11-26	Genelabs Technologies, Inc.	Sequence-directed DNA-binding molecules compositions and methods
GB9116470D0 (en)	1991-07-30	1991-09-11	Erba Carlo Spa	2-(imidazol-1-yl)-benzylethylidene-aminoxyalkanoic acid derivatives
WO1993003729A1 (en)	1991-08-12	1993-03-04	Research Corporation Technologies, Inc.	N-substituted phenoxazines for treating multidrug resistant cancer cells
US5571799A (en)	1991-08-12	1996-11-05	Basco, Ltd.	(2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5972630A (en) *	1991-08-19	1999-10-26	Dade Behring Marburg Gmbh	Homogeneous immunoassays using enzyme inhibitors
US5217586A (en)	1992-01-09	1993-06-08	International Business Machines Corporation	Electrochemical tool for uniform metal removal during electropolishing
US5190972A (en)	1992-01-27	1993-03-02	The University Of Melbourne	Method of combatting cyclosporine organ toxicity with prostaglandin analogs
GB9204466D0 (en) *	1992-03-02	1992-04-15	Sandoz Ltd	Improvements in or relating to organic compounds
GB9206648D0 (en)	1992-03-26	1992-05-06	Leo Pharm Prod Ltd	Chemical compounds
US5637317A (en)	1992-05-18	1997-06-10	Dietl; Hans	Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
EP0570829B1 (de)	1992-05-18	2001-04-25	CicloMulsion AG	Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur intravenösen Applikation sowie Verfahren zu ihrer Herstellung
HU213553B (en)	1992-05-25	1997-07-28	Biogal Gyogyszergyar	Process for isolating of cyclosporin-a
WO1993025533A1 (en)	1992-06-05	1993-12-23	Abbott Laboratories	Methods and reagents for the determination of immunosuppressive agents
US5527820A (en)	1992-06-23	1996-06-18	Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai	Antibiotics having immunosuppressive activity, delaminomycins and processes for the production of the same
GB9214202D0 (en)	1992-07-03	1992-08-12	Leo Pharm Prod Ltd	Chemical compounds
EP0578616A3 (en)	1992-07-09	1994-06-01	Sandoz Ltd	Cylosporin synthetase
SK277092A3 (en)	1992-09-07	1996-08-07	Galena As	Medicaments with n-methylated cyclic undecapeptides
GB9220439D0 (en)	1992-09-28	1992-11-11	Leo Pharm Prod Ltd	Chemical compounds
US5318895A (en)	1992-10-05	1994-06-07	Merck & Co., Inc.	Aspergillus niger mutants
US5589458A (en)	1992-11-13	1996-12-31	Thomas Jefferson University	Compounds that inhibit T cell proliferation and methods for using the same
US5298523A (en)	1992-12-14	1994-03-29	Harbor Branch Oceanographic Institution, Inc.	Method for treating transplant patients using mycalamide compounds
GB9226877D0 (en)	1992-12-23	1993-02-17	Leo Pharm Prod Ltd	Chemical compounds
CA2086267A1 (en)	1992-12-24	1994-06-25	Argyrios Margaritis	Cyclosporin derivatives and derivative conjugates
FI92334C (fi)	1992-12-30	1994-10-25	Leiras Oy	Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
US5393669A (en)	1993-02-05	1995-02-28	Martek Biosciences Corp.	Compositions and methods for protein structural determinations
WO1994018317A1 (en)	1993-02-12	1994-08-18	The Board Of Trustees Of The Leland Stanford Junior University	Regulated transcription of targeted genes and other biological events
US5834266A (en)	1993-02-12	1998-11-10	President & Fellows Of Harvard College	Regulated apoptosis
US5665383A (en)	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of immunostimulating agents for in vivo delivery
AU673057B2 (en)	1993-02-22	1996-10-24	Abraxis Bioscience, Llc	Methods for (in vivo) delivery of biologics and compositionsuseful therefor
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en)	1993-02-22	1997-09-09	Vivorx Pharmaceuticals, Inc.	Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5650156A (en)	1993-02-22	1997-07-22	Vivorx Pharmaceuticals, Inc.	Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5468772A (en)	1993-03-10	1995-11-21	Pharmagenesis, Inc.	Tripterinin compound and method
WO1994023733A1 (de)	1993-04-20	1994-10-27	Dr. Rentschler Arzneimittel Gmbh & Co.	Neue pharmazeutische zubereitungen zur oralen verabreichung enthaltend cyclosporin
EP0696323A1 (de)	1993-04-23	1996-02-14	Novartis AG	Rekombinante alanin racemase und gadph aus tolypocladium niveum
AU674233B2 (en)	1993-05-04	1996-12-12	Merck & Co., Inc.	Cyclohexapeptidyl aminoalkyl ethers
DE4338086A1 (de)	1993-11-08	1995-05-11	Dietl Hans	Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur oralen Applikation sowie Verfahren zu ihrer Herstellung
AU7276594A (en)	1993-08-13	1995-03-14	Banyu Pharmaceutical Co., Ltd.	Endothelin-antagonistic cyclopentane derivative
CA2169737C (en)	1993-08-18	2003-04-15	Kiyofumi Ishikawa	Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5421987A (en)	1993-08-30	1995-06-06	Tzanavaras; George	Precision high rate electroplating cell and method
US5510239A (en)	1993-10-18	1996-04-23	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of multidrug resistance-associated protein
DE10199039I2 (de)	1993-10-22	2008-08-07	Hexal Ag Ind 25	Pharmazeutische zusammensetzung mit cyclosporin a, einen vitamin e derivat und einen emulgator
KR20040068613A (ko)	1994-03-25	2004-07-31	이소테크니카 인코포레이티드	중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
JPH07278187A (ja)	1994-04-07	1995-10-24	Nippon Shinyaku Co Ltd	シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US5798386A (en)	1994-08-03	1998-08-25	Cell Therapeutics, Inc.	Angiogenic lipid formulations
US5639852A (en)	1994-09-01	1997-06-17	Wisconsin Alumni Research Foundation	Immunostimulatory agents
US5948693A (en)	1994-09-01	1999-09-07	Wisconsin Alumni Research Foundation	Solid phase synthesis of immunosuppressive agents
US5567300A (en)	1994-09-02	1996-10-22	Ibm Corporation	Electrochemical metal removal technique for planarization of surfaces
US5554725A (en)	1994-09-14	1996-09-10	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Synthesis of dolastatin 15
DE4433101A1 (de)	1994-09-16	1996-03-21	Bauer Kurt Heinz Prof Dr	Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
HU215966B (hu)	1994-11-21	1999-07-28	BIOGAL Gyógyszergyár Rt.	Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US5648376A (en)	1995-01-19	1997-07-15	Pharmagenesis, Inc.	Immunosuppressant diterpene compound
SE520730C2 (sv)	1995-01-20	2003-08-19	Eskil Elmer	Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
IE75744B1 (en)	1995-04-03	1997-09-24	Elan Corp Plc	Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5668734A (en)	1995-04-10	1997-09-16	The Uab Research Foundation	Method for analyzing 2D transferred noesy spectra of molecules undergoing multistate conformational exchange
AU692255B2 (en)	1995-04-24	1998-06-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Self-emulsifiable formulation producing an oil-in-water emulsion
JP3934705B2 (ja)	1995-05-26	2007-06-20	ノバルティスファーマ株式会社	サイクロデキストリン組成物
US5616595A (en)	1995-06-07	1997-04-01	Abbott Laboratories	Process for recovering water insoluble compounds from a fermentation broth
US5624902A (en) *	1995-06-07	1997-04-29	Torrey Pines Institute For Molecular Studies	Peptide inhibitors of calmodulin
DE19521974A1 (de)	1995-06-16	1996-12-19	Hexal Pharmaforschung Gmbh	Pharmazeutische Zubereitung mit Cyclosporin A
HUP9900405A3 (en)	1995-07-17	2001-04-28	Scynexis Inc Durham	Cyclosporin derivatives with anti-hiv effect
JPH0978187A (ja)	1995-09-07	1997-03-25	Daido Steel Co Ltd	メッキ用快削鋼
GB9601120D0 (en)	1996-01-19	1996-03-20	Sandoz Ltd	Organic compounds
CA2248192A1 (en)	1996-03-12	1997-09-18	Picower Institute For Medical Research	Treatment of hiv-infection by interfering with host cell cyclophilin receptor activity
US5840305A (en)	1996-03-14	1998-11-24	The Picower Institute For Medical Research	Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
AUPN880396A0 (en)	1996-03-21	1996-04-18	Fremantle Hospital	Animal model for transplantation
DE19611094C2 (de)	1996-03-21	1999-06-17	Dresden Arzneimittel	Verfahren zur Reinigung von Cyclosporin A und/oder verwandten Cyclosporinen aus einem Cyclosporin-haltigen Rohextrakt unter Anwendung chromatographischer Verfahren mit Kieselgel als Adsorbens
JPH1029979A (ja)	1996-04-12	1998-02-03	Ajinomoto Co Inc	新規ピリジン誘導体
US5750510A (en) *	1997-04-04	1998-05-12	Abbott Laboratories	3-descladinose-2,3-anhydroerythromycin derivatives
US5709797A (en)	1996-06-05	1998-01-20	Poli Industria Chimica S.P.A.	Method of isolating cyclosporins
US5747330A (en)	1996-06-05	1998-05-05	Poli Industria Chimica	Antibiotic producing microbe
EP1017366A4 (en)	1996-09-01	2006-03-22	Pharmos Corp	SOLID COPARCIPITATES FOR IMPROVED BIOVERABILITY OF LIPOPHILIC SUBSTANCES
GB9619894D0 (en)	1996-09-24	1996-11-06	Celltech Therapeutics Ltd	Pharmaceutical products
WO1998013024A2 (en)	1996-09-27	1998-04-02	Hyal Pharmaceutical Corporation	Hyaluronic drug delivery system
NZ336225A (en)	1996-12-12	2001-03-30	Dds Drug Delivery Service Ges	Preparation in form of a matrix material-auxiliary agent compound containing optionally an active substance
FR2757520B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757521B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr)	1996-12-24	1999-01-29	Rhone Poulenc Rorer Sa	Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5843520A (en)	1997-01-13	1998-12-01	Vanguard International Semiconductor Corporation	Substrate clamp design for minimizing substrate to clamp sticking during thermal processing of thermally flowable layers
JPH10251137A (ja)	1997-03-14	1998-09-22	Advanced Sukin Res Kenkyusho:Kk	光線過敏症抑制剤
FR2762843B1 (fr)	1997-04-30	1999-12-10	Rhone Poulenc Rorer Sa	Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5939406A (en) *	1997-07-21	1999-08-17	Wisconsin Alumni Research Foundation	18-substituted-19-nor-vitamin D compounds
AU9203898A (en)	1997-08-26	1999-03-16	Wisconsin Alumni Research Foundation	Cyclosporin a conjugates and uses therefor
DE69840586D1 (de)	1997-10-08	2009-04-02	Isotechnika Inc	Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
US20030220234A1 (en)	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
FR2772768B1 (fr) *	1997-12-19	2000-01-14	Rhone Poulenc Rorer Sa	Nouveau procede de preparation de derives de cyclosporine
US6706691B1 (en)	1998-07-15	2004-03-16	Board Of Regents, The University Of Texas System	Immunosupportive drug sparing diet
US6187152B1 (en)	1998-07-17	2001-02-13	Cutek Research, Inc.	Multiple station processing chamber and method for depositing and/or removing material on a substrate
US6183611B1 (en)	1998-07-17	2001-02-06	Cutek Research, Inc.	Method and apparatus for the disposal of processing fluid used to deposit and/or remove material on a substrate
FI110094B (fi)	1999-09-10	2002-11-29	Ecospec Ltd Oy	Menetelmä maanparannusaineen valmistamiseksi
IL148685A0 (en)	1999-09-21	2002-09-12	Rtp Pharma Inc	Surface modified particulate compositions of biologically active substances
EP1408930A1 (de)	1999-10-20	2004-04-21	Vesifact Ag	Cyclosporine enthaltende mikroemulsion-prekonzentrate und mikroemulsionen
US6613793B2 (en)	2001-07-02	2003-09-02	Dabur Research Foundation	Anticancer activity of imino acid conjugates or methylglyoxal
CA2727642C (en)	2001-10-19	2014-02-04	Isotechnika Inc.	Synthesis of cyclosporin analogs
ATE332917T1 (de) *	2001-10-19	2006-08-15	Isotechnika Inc	Synthese von cyclosporin-analogen
US7012065B2 (en)	2003-02-07	2006-03-14	Enanta Pharmaceuticals, Inc.	Cyclosporins for the treatment of immune disorders
WO2004082629A2 (en)	2003-03-17	2004-09-30	Albany Molecular Research, Inc.	Novel cyclosporins

2002
- 2002-10-17 AT AT02767027T patent/ATE332917T1/de active
- 2002-10-17 AT AT06013976T patent/ATE425178T1/de active
- 2002-10-17 DK DK02767027T patent/DK1436321T3/da active
- 2002-10-17 NZ NZ53194402A patent/NZ531944A/xx not_active IP Right Cessation
- 2002-10-17 ES ES02767027T patent/ES2266564T3/es not_active Expired - Lifetime
- 2002-10-17 CA CA2461740A patent/CA2461740C/en not_active Expired - Lifetime
- 2002-10-17 RU RU2004110940A patent/RU2321593C9/ru active
- 2002-10-17 DE DE60231570T patent/DE60231570D1/de not_active Expired - Lifetime
- 2002-10-17 IL IL16076302A patent/IL160763A0/xx unknown
- 2002-10-17 DE DE2002613115 patent/DE60213115T2/de not_active Expired - Lifetime
- 2002-10-17 HR HRP20040355AA patent/HRP20040355B1/hr not_active IP Right Cessation
- 2002-10-17 PL PL370772A patent/PL210841B1/pl unknown
- 2002-10-17 US US10/274,255 patent/US6998385B2/en not_active Ceased
- 2002-10-17 MX MXPA04003625A patent/MXPA04003625A/es active IP Right Grant
- 2002-10-17 EP EP20020767027 patent/EP1436321B9/en not_active Expired - Lifetime
- 2002-10-17 PT PT06013976T patent/PT1714977E/pt unknown
- 2002-10-17 CN CNB028207998A patent/CN100334106C/zh not_active Expired - Lifetime
- 2002-10-17 AU AU2002331509A patent/AU2002331509B2/en not_active Expired
- 2002-10-17 BR BRPI0213658A patent/BRPI0213658A8/pt not_active Application Discontinuation
- 2002-10-17 PT PT02767027T patent/PT1436321E/pt unknown
- 2002-10-17 SI SI200230376T patent/SI1436321T1/sl unknown
- 2002-10-17 EP EP20060013976 patent/EP1714977B1/en not_active Expired - Lifetime
- 2002-10-17 ES ES06013976T patent/ES2326040T3/es not_active Expired - Lifetime
- 2002-10-17 DK DK06013976T patent/DK1714977T3/da active
- 2002-10-17 HR HRP20070058AA patent/HRP20070058B1/hr not_active IP Right Cessation
- 2002-10-17 KR KR1020097022767A patent/KR101006206B1/ko not_active Expired - Lifetime
- 2002-10-17 PL PL392749A patent/PL210795B1/pl unknown
- 2002-10-17 WO PCT/CA2002/001559 patent/WO2003033526A2/en not_active Ceased
- 2002-10-17 US US10/274,437 patent/US7141648B2/en not_active Expired - Lifetime
- 2002-10-17 JP JP2003536264A patent/JP4261355B2/ja not_active Expired - Lifetime
- 2002-10-17 KR KR1020047005699A patent/KR100982466B1/ko not_active Expired - Lifetime
2004
- 2004-03-05 IL IL160763A patent/IL160763A/en active IP Right Grant
- 2004-03-23 ZA ZA2004/02269A patent/ZA200402269B/en unknown
- 2004-03-26 MA MA27597A patent/MA27293A1/fr unknown
- 2004-04-16 TN TNP2004000068A patent/TNSN04068A1/en unknown
- 2004-04-19 CO CO04035670A patent/CO5580836A2/es not_active Application Discontinuation
- 2004-05-14 NO NO20042031A patent/NO332459B1/no not_active IP Right Cessation
2005
- 2005-04-28 US US11/118,830 patent/US7332472B2/en not_active Expired - Lifetime
2006
- 2006-07-27 CY CY20061101044T patent/CY1105111T1/el unknown
- 2006-10-13 US US11/549,575 patent/US20070087963A1/en not_active Abandoned
2007
- 2007-09-20 IL IL186140A patent/IL186140A/en active IP Right Grant
2008
- 2008-01-03 US US11/969,174 patent/US20080171850A1/en not_active Abandoned
- 2008-10-21 JP JP2008271446A patent/JP4887469B2/ja not_active Expired - Lifetime
2009
- 2009-09-08 US US12/555,787 patent/US20100062976A1/en not_active Abandoned
2010
- 2010-06-08 US US12/796,616 patent/US20100311944A1/en not_active Abandoned
- 2010-07-30 AU AU2010206069A patent/AU2010206069A1/en not_active Abandoned
- 2010-08-19 JP JP2010184229A patent/JP5396571B2/ja not_active Expired - Lifetime
2012
- 2012-11-26 US US13/684,574 patent/US20130078280A1/en not_active Abandoned
2013
- 2013-09-30 US US14/042,226 patent/US20140142277A1/en not_active Abandoned
2014
- 2014-06-30 US US14/320,408 patent/USRE48226E1/en not_active Expired - Lifetime
- 2014-07-04 US US14/324,146 patent/US20140370082A1/en not_active Abandoned
2015
- 2015-11-23 US US14/949,616 patent/US9765119B2/en not_active Expired - Fee Related
2017
- 2017-08-14 US US15/676,851 patent/US10472394B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1714977A3 (en)	2007-01-10
US20130078280A1 (en)	2013-03-28
CN1571795A (zh)	2005-01-26
CA2461740A1 (en)	2003-04-24
CY1105111T1 (el)	2010-03-03
AU2002331509B2 (en)	2007-12-06
NO20042031L (no)	2004-05-19
NO332459B1 (no)	2012-09-24
US7141648B2 (en)	2006-11-28
AU2010206069A1 (en)	2010-08-19
JP5396571B2 (ja)	2014-01-22
DE60231570D1 (de)	2009-04-23
KR101006206B1 (ko)	2011-01-07
DE60213115D1 (en)	2006-08-24
HK1062568A1 (en)	2004-11-12
BRPI0213658A8 (pt)	2016-12-06
EP1714977B1 (en)	2009-03-11
HRP20040355B1 (hr)	2012-10-31
US7332472B2 (en)	2008-02-19
IL186140A (en)	2012-02-29
ES2266564T3 (es)	2007-03-01
US20100311944A1 (en)	2010-12-09
PL210795B1 (pl)	2012-03-30
US20140142277A1 (en)	2014-05-22
US20140370082A1 (en)	2014-12-18
RU2321593C2 (ru)	2008-04-10
KR20050037417A (ko)	2005-04-21
WO2003033526A3 (en)	2004-02-12
IL160763A (en)	2009-11-18
CO5580836A2 (es)	2005-11-30
WO2003033526A2 (en)	2003-04-24
KR100982466B1 (ko)	2010-09-16
JP4887469B2 (ja)	2012-02-29
US10472394B2 (en)	2019-11-12
ZA200402269B (en)	2005-05-25
CN100334106C (zh)	2007-08-29
DE60213115T2 (de)	2007-02-01
DK1714977T3 (da)	2009-07-06
DK1436321T3 (da)	2006-11-13
US20070087963A1 (en)	2007-04-19
IL160763A0 (en)	2004-08-31
ATE425178T1 (de)	2009-03-15
SI1436321T1 (sl)	2006-12-31
PT1714977E (pt)	2009-06-23
US20080171850A1 (en)	2008-07-17
US20170362277A1 (en)	2017-12-21
JP2010280710A (ja)	2010-12-16
US6998385B2 (en)	2006-02-14
USRE48226E1 (en)	2020-09-29
US9765119B2 (en)	2017-09-19
US20160075741A1 (en)	2016-03-17
EP1436321B1 (en)	2006-07-12
JP2005516893A (ja)	2005-06-09
HRP20070058A2 (en)	2008-09-30
KR20090130195A (ko)	2009-12-18
ES2326040T3 (es)	2009-09-29
NZ531944A (en)	2006-03-31
EP1436321A2 (en)	2004-07-14
HRP20040355A2 (en)	2005-04-30
JP2009046515A (ja)	2009-03-05
PL210841B1 (pl)	2012-03-30
PL370772A1 (en)	2005-05-30
ATE332917T1 (de)	2006-08-15
RU2321593C9 (ru)	2008-06-20
US20050192214A1 (en)	2005-09-01
RU2004110940A (ru)	2005-06-27
EP1714977A2 (en)	2006-10-25
JP4261355B2 (ja)	2009-04-30
EP1436321B9 (en)	2008-11-12
US20030139326A1 (en)	2003-07-24
CA2461740C (en)	2013-02-12
TNSN04068A1 (en)	2006-06-01
MA27293A1 (fr)	2005-05-02
US20100062976A1 (en)	2010-03-11
IL186140A0 (en)	2008-01-20
US20030212249A1 (en)	2003-11-13
PL392749A1 (pl)	2011-01-03
HRP20070058B1 (hr)	2014-05-23
BR0213658A (pt)	2004-10-26
MXPA04003625A (es)	2004-12-02

Publication	Publication Date	Title
PT1436321E (pt)	2006-10-31	Sintese de analogos de ciclosporina
MY187182A (en)	2021-09-08	Cyclosporine analogue mixtures and their use as immunomodulating agents
JO2034B1 (en)	1999-05-15	Isotopes of the hormone peptide its uses and the chemical compounds it contains
ATE245435T1 (de)	2003-08-15	Totalsynthese des amino hip analogen von didemnin a
BR0202204A (pt)	2003-04-01	Formulações estabilizadas
YU33204A (sh)	2006-08-17	Sinteza analoga ciklosporina
DK1250337T3 (da)	2009-03-30	Substituerede homopiperidinylbenzimidazol-analoger som fundus-relaksanter
YU33004A (sh)	2006-08-17	Smeša analoga ciklosporina i njihova upotreba u svojstvu imunomodulatornih supstanci
BR0000850B1 (pt)	2010-10-19	mistura de 3-metiloct-6-enóis 6-substituìdos, composição adorante contendo a referida mistura, bem como seu uso.
UY27523A1 (es)	2003-05-30	Tetra-, penta-, hexa-y heptapéptidos con actividad antiangiogénica
RU2002129529A (ru)	2004-06-27	Модифицирующая смесь
CA2352275A1 (en)	2000-06-02	Il-5 inhibiting 6-azauracil derivatives
MY131116A (en)	2007-07-31	Olefin polymerization catalyst composition comprising group 13 amide